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blindness, kidney failure, extremity amputations, and other chronic conditions. The objectives
of this study were 1) to estimate the direct medical and indirect productivity-related costs
attributable to diabetes and 2) to calculate and compare the total and per capita medical expen-
ditures for people with and without diabetes.
RESEARCH DESIGN AND METHODS — Medical expenditures were estimated for the
U.S. population with and without diabetes in 2002 by sex, age, race/ethnicity, type of medical
condition,andhealthcaresetting.Healthcareuseandtotalhealthcareexpendituresattributable
to diabetes were estimated using etiological fractions, calculated based on national health care
survey data. The value of lost productivity attributable to diabetes was also estimated based on
estimates of lost workdays, restricted activity days, prevalence of permanent disability, and
mortality attributable to diabetes.
RESULTS — Direct medical and indirect expenditures attributable to diabetes in 2002 were
estimatedat$132billion.Directmedicalexpendituresalonetotaled$91.8billionandcomprised
$23.2 billion for diabetes care, $24.6 billion for chronic complications attributable to diabetes,
and $44.1 billion for excess prevalence of general medical conditions. Inpatient days (43.9%),
nursing home care (15.1%), and ofﬁce visits (10.9%) constituted the major expenditure groups
by service settings. In addition, 51.8% of direct medical expenditures were incurred by people
65 years old. Attributable indirect expenditures resulting from lost workdays, restricted ac-
tivity days, mortality, and permanent disability due to diabetes totaled $39.8 billion. U.S. health
expendituresforthehealthcarecomponentsincludedinthestudytotaled$865billion,ofwhich
$160 billion was incurred by people with diabetes. Per capita medical expenditures totaled
$13,243 for people with diabetes and $2,560 for people without diabetes. When adjusting for
differences in age, sex, and race/ethnicity between the population with and without diabetes,
people with diabetes had medical expenditures that were 2.4 times higher than expenditures
that would be incurred by the same group in the absence of diabetes.
CONCLUSIONS — Theestimated$132billioncostlikelyunderestimatesthetrueburdenof
diabetes because it omits intangibles, such as pain and suffering, care provided by nonpaid
caregivers, and several areas of health care spending where people with diabetes probably use
services at higher rates than people without diabetes (e.g., dental care, optometry care, and the
use of licensed dietitians). In addition, the cost estimate excludes undiagnosed cases of diabetes.
Healthcarespendingin2002forpeoplewithdiabetesismorethandoublewhatspendingwould
be without diabetes. Diabetes imposes a substantial cost burden to society and, in particular, to
those individuals with diabetes and their families. Eliminating or reducing the health problems
caused by diabetes through factors such as better access to preventive care, more widespread
diagnosis, more intensive disease management, and the advent of new medical technologies
could signiﬁcantly improve the quality of life for people with diabetes and their families while at
the same time potentially reducing national expenditures for health care services and increasing
productivity in the U.S. economy.
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D
iabetes cost the U.S. an estimated
$132 billion in 2002 in medical ex-
penditures and lost productivity.
Across the components of the health care
system included in this study, per capita
direct medical expenditures for the
12.1 million people diagnosed with di-
abetes in the U.S. are more than double
the expenditures of otherwise similar
people without diabetes. A total of $92
billion in direct medical expenditures are
attributable to diabetes. Diabetes is asso-
ciated with higher rates of lost work time,
disability, and premature mortality. The
resulting economic loss to the U.S. econ-
omy in 2002 alone is estimated to be $40
billion. This cost estimate documents the
extraordinary national economic burden
of diabetes. Even so, such estimates do
not account for the losses attributable to
pain and suffering incurred by people
with diabetes, as well as to families and
friends of those with diabetes.
The prevalence of diabetes increases
with age and is higher among certain ra-
cial and ethnic minority populations. The
growth, aging, and increasing racial and
ethnic diversity of the U.S. population
portends a substantial increase in the size
of the population with diabetes. If diabe-
tes prevalence rates remained constant
over time, controlling for age, sex, race,
and ethnicity, then based on Census Bu-
reaupopulationprojections(1),thenum-
ber of people diagnosed with diabetes
could increase to 14.5 million by 2010
and to 17.4 million by 2020. The pro-
jected increase in the number of people
with diabetes suggests that the annual
cost in 2002 dollars of diabetes could rise
to an estimated $156 billion by 2010 and
to$192billionby2020.Theactualcostin
future years could be higher if the cost of
health care outpaces the overall cost of
living, or if the growing problem of obe-
sity increases the prevalence of type 2
diabetes.
This national cost estimate represents
an increase from estimates reported in
earlier studies, reﬂecting the growing
prevalence of diabetes in the U.S. and the
increasing cost of health care services.
Comparison of national cost estimates
across studies is complicated by differ-
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each study, the continuing growth and
aging of the U.S. population, and changes
over time in the cost of health care ser-
vices. The previous American Diabetes
Association (ADA) study on the cost of
diabetes estimated the national cost of di-
abetes in 1997 to be $98 billion (2).
Documenting the national economic
impactofdiabetescaninformpriorityset-
ting in health care research and delivery,
including prevention, diagnosis, and
treatment of diabetes.
Unless speciﬁcally noted, this study
uses prevalence-based cost-of-illness
methods similar to the approach used by
ADA (2,3). The following is an overview
of the research design and methods used
for this study, a discussion of important
ﬁndings, and a summary of the implica-
tions of these ﬁndings, limitations of the
study, and suggestions for future re-
search.
RESEARCH DESIGN AND
METHODS— The approach used to
estimate the cost of diabetes follows, to
the extent possible, the approach used in
previous studies of the cost of diabetes
and,inparticular,ADA’spreviouscostes-
timate (2). This approach has found ac-
ceptance in the general cost-of-disease
literature. Deviations from the approach
usedpreviouslybyADA(2)arenotedand
occur in some instances when the exact
approach used in the earlier study could
not be determined or when new data
sources and analytical tools enable im-
provementstopastapproaches.Belowisa
summary of the approach used to esti-
mate 1) the size of the population with
diabetes, 2) health care use and total
health care expenditures attributable to
diabetes, and 3) the value of lost produc-
tivity attributable to diabetes.
Estimating the size of the population
with diabetes
This national cost estimate is based on an
estimateof12.1millionpeopleintheU.S.
in 2002 who have been diagnosed with
diabetes. This estimate of the magnitude
of the diabetic population represents an
increaseof1million(9%)fromyear2000
estimates and an increase of 1.8 million
(17%)fromyear1997estimates.Basedon
results from the 2000 Census, it appears
that during the period of 1990–2000, the
U.S. population grew faster than pro-
jected by the Census Bureau. (The actual
U.S. population in 2000, based on the
2000 Census, exceeded the Census Bu-
reau’s pre-2000 projections of the U.S.
population in 2000 by 6.8 million indi-
viduals [or 2.4% of the total population].
One implication is that pre-2000 esti-
mates of the number of people with dia-
betes in the U.S. were biased downward
because the sample weights used in sur-
veys such as the National Health Inter-
view Survey (NHIS) were based on
CensusBureaupopulationestimates.)Itis
based on self-reported prevalence of dia-
betes only; therefore, it does not account
for the considerable number of people
with diabetes who are unaware that they
have the disease or do not report it. In-
deed, the ADA estimates that as many as
one-third of people with diabetes are un-
aware that they have the disease. Further,
this estimate excludes women with gesta-
tional diabetes.
This cost estimate is based on preva-
lence rates derived from the combined
1998, 1999, and 2000 ﬁles of the NHIS.
Combining 3 years’ worth of NHIS ﬁles
created larger samples with which to esti-
mate separate prevalence rates for each of
12 age-groups by sex and by four race/
ethnicity designations. (The 12 age cate-
gories are 0–17, 18–24, 25–29, 30–34,
35–39, 40–44, 45–49, 50–54, 55–59,
60–64, 65–69, and 70 years. The four
race/ethnicity categories are Hispanic,
non-Hispanic white, non-Hispanic black,
and non-Hispanic other.)
The NHIS collects data on 43,000
households of more than 106,000 people
annually. The combined ﬁles for 1998–
2000 create a sample of more than
320,000 people. People with diabetes are
identiﬁed using the survey question that
asks whether the survey participant has
been told by a doctor that he or she has
diabetes(otherthangestationaldiabetes).
Responses to the question are coded as
“yes,”“ no,”“ borderline,” and “no re-
sponse.” People responding “yes” are
coded as having diabetes. People re-
sponding “borderline” are not counted as
having diabetes in this analysis.
As shown in Figs. 1 and 2, diabetes
prevalence rates increase with age. Preva-
lence rates vary substantially by race and
ethnicity. They are higher for Hispanics
and non-Hispanic blacks than for non-
Hispanic whites. Furthermore, the rates
for other populations (i.e., Asian Ameri-
cans, American Indians, Paciﬁc Islanders,
etc.) are similar to those of non-Hispanic
whitesamongfemalesbutarehigherthan
the rates for non-Hispanic whites among
males.
Applyingtheseprevalenceratestothe
size of the U.S. population in each demo-
graphicgroup,asdeterminedbythe2000
Census and projected to 2002 using Cen-
sus Bureau estimates, produced the esti-
mate of 12.1 million people diagnosed
with diabetes.
If diabetes prevalence rates within a
demographic group remained constant
over time, then, based on Census Bureau
population projections (1), the size of the
population with diabetes will grow to
14.5 million by 2010 and to 17.4 mil-
lion by 2020 (Table 1). Whereas the U.S.
population is projected to increase by
17% between 2002 and 2020, the size
ofthepopulationdiagnosedwithdiabetes
is projected to increase by 44% due, in
largepart,totheincreaseinthesizeofthe
elderly population and the increasing ra-
cial and ethnic diversity of the U.S. pop-
ulation. Changing demographic
characteristics will contribute to an in-
crease in the overall prevalence rate for
diagnosed cases of diabetes from 4.2% in
2002 to a projected 5.2% in 2020.
The number of Hispanics and other
minority populations diagnosed with di-
abetes is projected to double between
2002 and 2020, whereas the number of
non-Hispanic blacks and non-Hispanic
whites diagnosed with diabetes is pro-
jected to increase by 50 and 27%, respec-
tively.
Although there is no projected in-
crease in the total number of people un-
der age 45 years diagnosed with diabetes
between 2002 and 2020, the projected
increasesforpopulationsaged45–64and
65 years are 48 and 56%, respectively.
Health resource use attributable to
diabetes
In addition to receiving health care ser-
vices for medical conditions directly re-
lated to diabetes, people with diabetes are
atgreaterriskforneurologicaldisease,pe-
ripheral vascular disease, cardiovascular
disease, renal disease, endocrine/
metaboliccomplications,ophthalmicdis-
ease, and other chronic complications
compared with individuals without dia-
betes. A portion of health care use associ-
ated with these medical conditions is
attributable to diabetes.
The general principle for estimating
the cost of diabetes in this analysis is
Report
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able to diabetes is determined by a com-
parison of the health care use patterns of
individuals with and without diabetes,
controlling for differences between the
two populations in demographic charac-
teristics that are potentially correlated
with the use of health care services (e.g.,
age, sex, and race/ethnicity).
Three limitations of the source data,
however, increase the complexity of the
analysis design and calculations. These
limitations are 1) absence of a single data
source for all estimates, 2) small sample
sizes for some items of interest, and 3)
underreporting of diabetes as a comor-
bidity. The implications of these limita-
tions and how we have addressed these
limitations are summarized below.
● No single source of data. Because no
single data source representative of the
U.S. population contains all of the in-
formation necessary to estimate the
health care cost of diabetes, it is neces-
sary to draw upon multiple data
sources. Among some of these sources
are differences in deﬁnitions for identi-
fying people with diabetes and differ-
ences in levels of detail to categorize
types of patient visits. One source of
complete data required to estimate di-
rect medical expenditures attributable
todiabetesisclaimsfromGroupHealth
of Puget Sound (GHPS). This data
source contains a diabetic ﬂag in a dis-
ease registry, but the GHPS sample
might not be representative of health
careusepatternsandcostsfortheentire
U.S. population. The Medical Expendi-
ture Panel Survey (MEPS) is closest to a
single, nationally representative source
of data in that it 1) identiﬁes people
with diabetes-related conditions, 2)
measures health care use, and 3) pro-
vides cost information. However,
MEPS is limited by the small sample
size.
● Small sample sizes for some items of
interests. Disaggregating the U.S. pop-
ulation by age, sex, race, and ethnicity
requires relatively large sample sizes to
obtain reliable estimates of differences
in use patterns by diabetes status when
analyzing speciﬁc medical conditions
associated with diabetes. The number
of identiﬁed people with diabetes who
participated in the most recent MEPS is
insufﬁcient to obtain reliable estimates
of health care use for some chronic
complications associated with diabetes
and in some health care settings. The
use of alternative data sources, such as
the National Ambulatory Medical Care
Survey,increasessamplesizebutishin-
dered by the third major limitation—
underreporting of diabetes as a
comorbidity.
● Underreporting of diabetes as a comor-
bidity. The literature reports that there
is signiﬁcant underreporting of diabe-
tes as a comorbidity in health care da-
tabases. Unless the attending physician
lists diabetes as a comorbidity on the
patient’smedicalrecord,thehealthcare
servicesprovidedtothatpatientarenot
linked to diabetes. Sources such as
GHPS and MEPS allow one to identify
whether a person has been diagnosed
with diabetes but, as discussed above,
their representativeness is often ques-
tioned (in the case of GHPS) or they
have insufﬁcient sample size.
Figure 1—Proportion of female population with conﬁrmed diabetes in 2002.
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asfollows.First,thestudyusesaneclectic
approach that combines ﬁndings from
empirical analysis of multiple data
sources with ﬁndings reported in the lit-
erature. Second, for several national sur-
veys completed annually, multiple years’
worth of data are pooled to increase sam-
ple size. Third, similar to previous stud-
ies, this study uses an attributable risk
methodology to estimate use of health
care services that can be attributed to di-
abetes.
Theattributableriskmethodologyes-
timates the odds of having a particular
medicalconditionbydiabetesstatus,then
combinestheseoddswithestimatesofthe
proportion of the population with diabe-
testocalculateanetiologicalfraction.The
etiological fraction represents an estimate
of the proportion of health care services
for a particular medical condition that is
attributable to diabetes. The etiological
fraction is calculated based on the follow-
ing:
Ei 
P  Ri  1
P  Ri  1  1
where Ei is the fraction of health care use
for medical condition “i” that is attribut-
able to diabetes, P represents the diabetes
prevalence rate, and Ri is the relative risk
ofdiseasei(i.e.,theoddsratio)forpeople
with diabetes compared with people
without diabetes.
Combining odds ratios estimated us-
ing the MEPS with diabetes prevalence
rates estimated using the NHIS creates
Figure 2—Proportion of male population with conﬁrmed diabetes in 2002.




Total population 288 307 335 17
Diagnosed with diabetes 12.1 14.5 17.4 44
Overall diabetes prevalence rate 4.2% 4.7% 5.2% 24
Race/ethnicity
Hispanic 1.4 2.0 2.9 107
Non-Hispanic white 8.1 9.1 10.3 27
Non-Hispanic black 2.0 2.5 3.0 50
Non-Hispanic other 0.6 0.9 1.2 100
Sex
M 5.8 7.1 8.6 48
F 6.3 7.4 8.8 40
Age (years)
45 2.1 2.0 2.1 0
45–64 5.2 7.0 7.7 48
65 4.8 5.5 7.5 56
Census Bureau (1) population projections adjusted using calibration factors that align Census Bureau
projections for the year 2000 with actual Census 2000 counts.
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ical conditions listed in Fig. 3 for each
demographic group modeled. This ﬁgure
combines etiological fractions across the
12age-groupsbyrace/ethnicityandsexto
present etiological fractions for the popu-
lation aged 45, 45–64, and 65 years.
The etiological fractions vary substan-
tially by age to reﬂect the changing prev-
alence of diabetes and differences in the
prevalence of speciﬁc medical conditions
by age. For example, for the populations
aged 45, 45–64, and 65 years, the
proportions of all health care use associ-
ated with neurological disease that is at-
tributable to diabetes are 6, 10, and 5%,
respectively. The medical condition with
the highest etiological fractions is cardio-
vasculardisease,wheretheproportionsof
all health care visits attributable to diabe-
tes for individuals aged 45, 45–64, and
65 years are 16, 20, and 17%, respec-
tively.
Although not reported here, the etio-
logical fractions vary substantially by race
and ethnicity, with the fractions generally
higher for Hispanics and non-whites
compared with non-Hispanic whites.
This ﬁnding is consistent with past re-
search that shows ethnic disparities in
both diabetes prevalence rates and the
rates of diabetic complications (4).
Table 2 summarizes the data sources
used to analyze each component of the
cost analysis and summarizes the unit
cost estimates. Sources of health care use
data include the 1998–2000 ﬁles of the
National Ambulatory Medical Care Sur-
vey, the 1998–2000 ﬁles of the National
Hospital Ambulatory Medical Care Sur-
vey, the 1999 National Inpatient Sample,
the1999NationalNursingHomeSurvey,
and the 1998 and 2000 ﬁles of the Na-
tional Home and Hospice Care Survey.
For each of these ﬁles, the primary
diagnosisisusedtoclassifythehealthcare
visit (or inpatient day) into one of nine
medical condition classiﬁcations: 1) dia-
beteswithoutcomplications,2)oneofthe
seven chronic medical conditions above
(i.e., neurological disease, peripheral vas-
cular disease, cardiovascular disease, re-
nal disease, endocrine/metabolic
complications, ophthalmic disease, and
other chronic complications), or 3) nei-
ther 1) nor 2), in which case the visit is
classiﬁed as a “general medical condi-
tion.” (See the APPENDIX for a list of diag-
nosis codes used to categorize visits and
hospital inpatient days by medical condi-
tion.)
Health care use rates for each of the
nine conditions in each health delivery
setting are estimated by patient age, sex,
and race/ethnicity. Combining these use
rates with etiological fractions and esti-
mates of population size for each demo-
graphic group produces national
estimatesofhealthcareuseattributableto
diabetes for each medical condition.
The1998MEPSistheprimarysource
for most estimates of the per-unit price of
health care services. Price estimates are
based on actual payment for services, not
charges. Price estimates from other
Figure 3—Etiological fractions, adjusted for race/ethnicity, sex, and ﬁner age-groupings. CVD, cardiovascular disease; GMC, general medical
conditions; PVD, peripheral vascular disease; OCC, other chronic complications.
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is readily available for more recent years
or when price estimates from the MEPS
appear unreliable (e.g., because of small
sample sizes in the MEPS). All price esti-
matesforhealthcareservicesareadjusted
to2002dollarsusingthemedicalcompo-
nent of the consumer price index. The
unit prices represent averages across all
patients irrespective of diabetes status or
reason for visit (neonatal inpatient stays
were omitted from the calculation of av-
erage cost per day). To the extent that the
unit price is higher when diabetes is a co-
morbidity, or that inpatient days and out-
patient visits tend to be more expensive
for the medical complications associated
with diabetes, the average unit cost might
underrepresent the true unit cost for ser-
vices attributable to diabetes.
Estimates of the average annual cost
of supplies for people using insulin and
oralagentswerecalculatedusingcostdata
from The Source Prescription Audit, the
2002RedBook(13),pharmaceuticalcom-
panies, and suppliers of devices used by
people taking insulin. Based on preva-
lenceratescomputedusingthecombined
1998–2000ﬁlesofNHISandestimatesof
the population in 2002, the estimated
number of people using oral agents for
diabetes and the estimated number of
people using insulin are 7.5 and 3.9 mil-
lion, respectively. The percentage of peo-
ple using insulin and oral agents varies
substantially by age, reﬂecting the in-
creasing proportion of cases involving
type 2 diabetes among the population
with diabetes in older age brackets. Not
all people with diabetes use either insulin
or oral agents, especially among the
younger age brackets.
Productivity foregone
People with diabetes are at greater risk of
temporary incapacity (deﬁned as lost
workdays and bed days), permanent dis-
ability, and premature mortality. The pe-
Table 2—Source of health resource use and price estimates




Hospital day 1999 NIS 1998 MEPS 2,385
Nursing home day 1999 NNHS Kiplinger (5) 169
Outpatient care
Ofﬁce-based physician encounter 1998–2000 NAMCS 1998 MEPS 160
Emergency department visit 1998–2000 NHAMCS 1998 MEPS 452
Ambulance service 1998–2000 NHAMCS AAA 247
Hospital outpatient and free-standing
ambulatory surgical center visit
1998–2000 NHAMCS 1998 MEPS 561
Outpatient medication 1998–2000 NAMCS,
1998–2000 NHAMCS
1998 MEPS 47
Home health visit 1998, 2000 NHHCS,
1998–2000 NHIS
1998 MEPS 89




Lost workday 1998–2000 NHIS BLS 168†
Restricted activity day 1998–2000 NHIS BLS 67†











Insulin use (supplies include glucose
monitoring supplies, insulin
delivery supplies, and insulin) and





Fertig et al. (11), Frost
and Sullivan (12)
2002 Red Book (13), 2002
The Source Prescription
Audit, Scott-Levin, 2002
AllegroMedical et al. (14),
2002 MiniMed (15)
1,778‡






CDC (17), NIDDK (18)
2002 Red Book (13) 666‡
*American Ambulance Association (AAA) estimate of the national average cost for a basic life support transport, adjusted to 2002 dollars; †actual estimate varies by
age-group and sex; ‡estimated annual cost per user. CDC, Centers for Disease Control and Prevention; NAMCS, National Ambulatory Medical Care Survey;
NHAMCS, National Hospital Ambulatory Medical Care Survey; NHHCS, National Home and Hospital Care Survey; NIS, National Inpatient Sample; NIDDK,
National Institute of Diabetes and Digestive and Kidney Diseases; NNHS, National Nursing Home Survey.
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calculated based on the average earnings
of the person whose productivity is fore-
gone. Bureau of Labor Statistics (BLS) es-
timates of year 2001 annual earnings by
age and sex for the civilian noninstitu-
tional population are used to estimate the
average cost per day of missing work, the
average cost per year of permanent dis-
ability, and the loss of expected lifetime
earnings resulting from premature mor-
tality (19,20). Earnings estimates for
2001 are inﬂated to 2002 dollars using
the overall consumer price index.
Lost workdays and bed days
The economic impact of temporary inca-
pacityduetodiabetescanbemeasuredby
both workdays lost and number of bed
days, because both capture physical limi-
tation due to diabetes that results in lost
productivity. These data are obtained
from the NHIS, in which respondents re-
port workdays lost and bed days during
the previous year due to illness. Lost
workdays are deﬁned as days in which a
person misses work at a job or business
becauseofdiabetesordiabetes-relatedin-
jury (excluding maternity leave). Bed
daysaredeﬁnedasdaysinwhichaperson
is kept in bed more than half of the day
becauseofdiabetesordiabetes-relatedin-
jury (including days while an overnight
patient at a hospital). Lost workdays are
subtractedfrombeddaystopreventover-
counting if a person has both a lost work-
day and a bed day.
An estimate of workdays lost due to
diabetes is found by comparing average
days lost by diabetes status for each age-
group and by sex. Controlling for age,
men with diabetes have 3.1 more lost
workdaysand7.9morebeddaysperyear,
on average, than men without diabetes.
Women with diabetes had 0.6 more lost
workdays and 8.1 more bed days, on av-
erage, than women without diabetes.
However, these estimates likely underes-
timate lost workdays to the extent that
men and women with diabetes are less
likely to be in the labor force than men
and women without diabetes.
The pecuniary value of a workday is
deﬁnedasaverageearningsfortheperson
incurringthelostworkday.Averageearn-
ings differ by age-group and sex, but the
average earnings for people with diabetes
who are between the ages of 18 and 64 is
estimated at $168 per day. Following the
approach used by Yassin et al. (21), the
cost per bed day is deﬁned as 40% of the
cost of a lost workday.
Disability
Peoplewithdiabetesareatgreaterriskfor
amputations, loss of vision, and other
physical problems that can limit their
earning potential or preclude them from
gainful employment. Ideally, estimating
lost earnings would entail comparing the
average earnings of all people with diabe-
testotheaverageearningsofpeoplewith-
outdiabetes,controllingfordifferencesin
demographic characteristics and other
factors that affect earning potential but
that are unrelated to diabetes. A compar-
ison of gross average earnings would cap-
ture both differences in labor force
participation patterns and the possibility
that an individual with diabetes will be in
a lower-paying job. Unfortunately, there
are no recent data that provide reliable
information with which to estimate aver-
age earnings by diabetes status while con-
trollingfordemographicandotherfactors
affecting earning potential.
Consequently, following the ap-
proach previously used by the ADA (2),
data from the Social Security Administra-
tionareusedtoestimatetheprevalenceof
total number of permanently disabled
workers attributable to diabetes. The So-
cial Security Disability Insurance (SSDI)
program provides beneﬁts to disabled
workers and their spouses or children
(whetherornottheyaredisabled),retired
workers and their dependent family
members, and survivors of deceased
workers. Individuals aged 18–64 years
who receive SSDI beneﬁts are included in
the estimate of lost productivity attrib-
uted to diabetes-related disability. The
Social Security Administration Ofﬁce of
Research, Evaluation, and Statistics com-
piles information on the total number of
people with disabilities by speciﬁed con-
dition. Therefore, using information on
the number of disabled workers as a per-
centage of the total number of beneﬁcia-
ries from Table 1 in the Annual Statistical
Report on the Social Security Disability
Insurance Program, 2000, we adjusted
the Social Security Administration data to
reﬂectthenumberofdisabledworkersby
speciﬁed condition.
As of January 2002, there were an es-
timated 122,000 people aged 18–64
years receiving SSDI beneﬁts where dia-
betes is listed as the primary basis of dis-
ability and another 109,000 people aged
18–64 years receiving SSDI beneﬁts
where diabetes is listed as the secondary
basis of disability. This study attributes to
diabetes100%ofthecaseswherediabetes
is the primary basis of disability and 50%
of the cases where diabetes is the second-
ary basis of disability. The number of
caseswherediabetesisacontributingfac-
tor to the disability, but where diabetes is
not listed as the primary or secondary di-
agnosis, was unavailable. Also, the num-
ber of unemployed people with diabetes
who are not receiving SSDI but who
would be employed in the absence of di-
abetesisunknown.Anestimated176,475
person-years of permanent disability in
2002 are attributable to diabetes. Each
case of permanent disability results in an
average lost earnings of $42,462 per year.
The national cost estimate excludes the
cost to family and friends caring for a per-
son with permanent disabilities attribut-
able to diabetes.
Mortality
Data from the 1998 Multiple Cause of
Death File (22) were used to determine
the total number of deaths attributable to
diabetes. The ﬁle reports causes of death,
alongwitheconomic,geographic,andde-
mographic information for deaths of all
U.S. citizens occurring within the U.S.
Mortality-related productivity costs
aretheestimatedvalueoflostfutureearn-
ings from paid market and unpaid house-
hold labor resulting from premature
death due to diabetes or diabetes-related
diseases. The estimated loss in annual
earnings is based on estimates of the pro-
portion of the population in the labor
force, estimates of annual mean earnings
from the BLS, and estimates of the mean
value of housekeeping services. The esti-
matedvalueoflosthousekeepingservices
for individuals not in the labor force is
40% of average earnings for people of
similar age and sex who are in the work
force and 20% of annual earnings for in-
dividuals in the labor force. Estimates of
the present value of lifetime future earn-
ings are based on human capital method-
ology,whichassumesthatearningsreﬂect
the contribution workers make to the
value of goods and services and that the
present value of expected future earnings
is an estimate of the value of human cap-
ital(23).Themortality-relatedproductiv-
ity loss estimate incorporates both the
number and timing ofpremature deaths at-
tributable to diabetes.
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theBureauofLaborStatistics,weupdated
the present value of future earnings
(PVFE) estimates from Haddix et al. (24).
The PVFE for 2002, including unpaid
householdwork,wasestimatedassuming
a4%realdiscountrate.TheaveragePVFE
estimate for all diabetes-attributed mor-
tality cases is $116,928, although the ac-
tual cost estimate differs by age and sex.
RESULTS
Health resource use attributable to
diabetes
From estimates of per capita health care
use and the size of the population, by de-
mographic group, this study estimates to-
tal health care use for each demographic
group. Applying the etiological fractions
for the corresponding demographic
groups results in estimates of health re-
source use attributable to diabetes.
Table 3 shows estimated health care
use by type of service aggregated into
three broad age-groups. The attributable
health care use due to diabetes is greatest
for the population aged 65 years, de-
spitethispopulationhavingslightlyfewer
people with diabetes than the population
aged 45–64 years. For instance, ofﬁce-
based physician encounters attributable
to diabetes for people over age 65 years is
more than double the ofﬁce-based physi-
cian encounters for people between 45
and 64 years. Use of emergency depart-
ment, home health, and hospice care ser-
vices is also substantially higher for the
population over age 65 years compared
with the population between age 45 and
64 years and the population under age 45
years.
Tables 4–6 provide information on
health care use attributable to diabetes by
medicalconditionandtypeofservice.Ta-
ble4showstotaluseofservicesbytypeof
medical condition attributable to diabe-
tes, Table 5 shows each medical condi-
tion’s proportion of total use attributable
to diabetes, and Table 6 shows the pro-
portion of total U.S. use attributable to
diabetes. Examination of these three ta-
bles reveals the following trends:
● Most of the health care use attributable
to diabetes is for the treatment of gen-
eral medical conditions, i.e., visits or
inpatient days where the primary diag-
nosis is neither diabetes nor one of the
seven chronic complications analyzed.
For example, 63% of hospital inpatient
days attributable to diabetes fall under
the category of general medical condi-
tions.
● Of the seven chronic complications an-
alyzed, cardiovascular disease accounts
for the largest proportion of health care
use attributable to diabetes. For exam-
ple, in 2002, an estimated 4 million
hospital inpatient days were attribut-
able to diabetes where the primary di-
agnosis is related to cardiovascular
disease. This constitutes 24% of total
hospital days attributable to diabetes
and 19% of total U.S. inpatient days
whentheprimarydiagnosiswasrelated
to cardiovascular disease.
● Diabetes accounts for a sizable increase
in the use of health care services. An
estimated 18% of home health visits in
the U.S. are attributable to diabetes.
Approximately 15% of nursing home
services and 14% of hospice care ser-




Health care expenditures attributable to
diabetes are those costs incurred by the
population with diabetes above what




Total 45 45–64 65
Institutional care
Hospital inpatient days 2,183 5,802 8,927 16,912
Nursing home days 15,141 32,805 34,406 82,352
Outpatient care
Ofﬁce-based physician encounters 11,555 16,718 34,365 62,638
Emergency department encounters 334 971 3,478 4,782
Hospital outpatient and free-
standing ambulatory surgical
center encounters
46 2,399 3,467 5,912
Home health visits 1,493 5,899 36,820 44,212
Hospice care days 48 430 4,616 5,094






vascular Cardiovascular Renal Metabolic Ophthalmic Other
Institutional care
Inpatient days 856 460 313 4,084 410 16 5 89 10,680 16,912
Nursing home days 25,296 7,948 941 12,628 2,600 107 9 161 32,663 82,352
Outpatient care
Physician ofﬁce visits 9,930 652 336 13,064 980 1,171 1,502 175 34,826 62,638
Emergency visits 309 65 31 690 166 4 19 41 3,456 4,782
Hospital outpatient visits 1,357 47 49 1,367 111 93 109 16 2,763 5,912
Home health visits 16,924 1,077 1,000 6,973 803 33 77 103 17,221 44,212
Hospice care days 121 39 9 698 52 1 0 0 4,175 5,094
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not have diabetes. Of the estimated $91.8
billion in health care expenditures attrib-
utable to diabetes, $47.6 billion (52%) is
forservicesprovidedtopeople65years
of age. An estimated $31.6 billion (34%)
is for services provided to people age
45–64 years, whereas the remaining
$12.6 billion (14%) is for services pro-
videdtopeopleunderage45years(Table
7). Home and hospice care expenditures
attributable to diabetes are incurred pri-
marily by the population 65 years of
age.
Table 8 shows estimates of attribut-
able health care expenditures by medical
condition and type of service. Expendi-
turesforhealthcareeventswithaprimary
diagnosis of uncomplicated diabetes and
diabetes-related supplies are estimated to
be$23.2billionfor2002,whichaccounts
for 25% of all health care attributable ex-
penditures.Atover$44billion(or48%of
total attributable expenditures), general
medical conditions comprise the largest
component of expenditures attributable
to diabetes. Together, the seven chronic
conditions associated with diabetes ac-
count for the remaining 27% of attribut-
able expenditures, with cardiovascular
disease being the single largest contributor.
Total U.S. expenditures for health
care services analyzed in this study are
estimatedat$865billion(Table9),which
is58%ofthetotalU.S.healthcareexpen-
ditures of approximately $1.5 trillion in
2002 (25). (Centers for Medicare and
Medicaid Services [CMMS] estimated na-
tional health care expenditures of $1.3
trillionintheyear2000,whichisadjusted
to 2002 using CMMS’s projection of an
8% increase in annual cost of health care
services in the U.S. resulting from rising
medical costs and an increased use of ser-
vices.) Cost components not included in
this analysis include such things as
school-based and public health clinics,
dental care, podiatric care, optometry
care and vision products (with the excep-
tionofophthalmologyservices,whichare
included), research, over-the-counter
medicines, and other areas. CMMS esti-
matesexpendituresin2000tobe$60bil-
lion for dental care, $44 billion for
government public health activities, and
$44 billion for investment (i.e., research
and construction). Martin et al. (26) esti-
mate expenditures in 1998 to be $16 bil-
lionforvisionproductsandothermedical
durables (e.g., hearing aides, medical
equipment rentals, etc.) and $122 billion
for over-the-counter medicine and sun-
dries.
This analysis focuses on those areas
where health care use patterns have been
shown to differ by diabetes status. There-
fore, it is unknown what portion of the
remaining 42% of U.S. health care costs
can be attributed to diabetes. Compo-






vascular Cardiovascular Renal Metabolic Ophthalmic Other
Institutional care
Inpatient days 5 3 2 24 2 0 0 1 63 100
Nursing home days 31 10 1 15 3 0 0 0 40 100
Outpatient care
Physician ofﬁce visits 16 1 1 21 2 2 2 0 56 100
Emergency visits 6 1 1 14 3 0 0 1 72 100
Hospital outpatient visits 23 1 1 23 2 2 2 0 47 100
Home health visits 38 2 2 16 2 0 0 0 39 100
Hospice care days 2 1 0 14 1 0 0 0 82 100
Data are %.






vascular Cardiovascular Renal Metabolic Ophthalmic Other
Institutional care
Inpatient days 100 7 8 19 10 13 8 3 8 9
Nursing home days 100 15 12 19 20 13 0 4 9 15
Outpatient care
Physician ofﬁce visits 100 8 6 20 8 14 6 2 5 7
Emergency visits 100 7 7 20 7 13 17 1 4 4
Hospital outpatient visits 100 9 8 22 8 14 12 1 4 7
Home health visits 100 7 9 19 12 7 9 3 11 18
Hospice care days 100 5 9 19 10 11 0 0 13 14
Data are %. *Differences across service types in the proportion of total health care use attributable to diabetes occur because the etiological fraction for a particular
medical condition differs by demographic group, and the demographic characteristics of patients receiving services differ by type of service.
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lyzed in this study, but where health care
use patterns might differ by diabetes sta-
tus include dentistry, podiatry, optome-
try, and licensed dietitians. It is known,
forexample,thatpeoplewithdiabetesare
at higher risk for periodontal disease than
the general population, but these data are
not incorporated here. Thus, it is likely
that this estimate of health care costs at-
tributable to diabetes underestimates the
true amount.
Of the health care components ana-
lyzed, more than $1 in $10 spent on
health care services in the U.S. is attribut-
able to diabetes. Expenditures attribut-
able to diabetes are greatest for hospital
inpatient stays ($40.3 billion), followed
by nursing home care ($13.9 billion) and
visits to physician ofﬁces ($10 billion).
Thecostoforalagentstolowerbloodglu-
cose,insulin,andinsulin-relatedsupplies
totaled approximately $12 billion. Diabe-
tesisresponsibleforasubstantialpropor-
tion of total U.S. expenditures for certain
health care services, e.g., 18% of home
health expenditures, 15% of nursing
home expenditures, and 14% of hospice
care expenditures.
The estimated cost to provide health
care services to people with diabetes ex-
ceeded $160 billion in 2002 (for those
components of the health care system in-
cluded in this study). This includes costs
attributable to diabetes as well as non–
diabetes-related costs. Although people
with diagnosed diabetes comprise only
slightly more than 4% of the U.S. popu-
lation, of the components of the health
caresystemincludedinthisstudy,almost
$1 of every $5 spent on health care in the
U.S. is for a person with diabetes.
Because the prevalence of type 2 dia-
betes increases with age, the population
with diabetes tends to be older compared





Table 7—Health care expenditures attributable to diabetes in the U.S., by age and type of service, 2002 (in millions of dollars)
Type of service
Age (years)
Total 45 45–64 65
Institutional care
Hospital inpatient days 5,207 13,838 21,293 40,337
Nursing home days 2,552 5,528 5,798 13,878
Outpatient care
Ofﬁce-based physician encounters 1,851 2,678 5,505 10,033
Emergency department encounters 151 439 1,572 2,162
Hospital outpatient and free-standing ambulatory
surgical center encounters
26 1,345 1,944 3,315
Home health visits 133 524 3,273 3,930
Hospice care days 5 46 492 543
Other expenditures
Ambulance services 28 40 77 146
Outpatient medication 756 1,991 2,769 5,516
Oral agents 533 2,318 2,157 5,009
Insulin and delivery supplies 1,355 2,891 2,745 6,991
Total 12,596 31,640 47,626 91,861



















Diabetes 2,043 1,591 761 140 4,263 1,504 13 12,916 23,231
Neurological symptoms 1,096 104 26 29 1,339 96 4 52 2,748
Peripheral vascular disease 746 54 27 14 159 89 1 31 1,121
Cardiovascular disease 9,740 2,093 767 312 2,128 620 74 1,892 17,626
Renal complications 977 157 62 75 438 71 6 92 1,879
Endocrine/metabolic
complications
38 188 52 2 18 3 0 126 426
Ophthalmic complications 11 241 61 9 2 7 0 92 422
Other complications 212 28 9 19 27 9 0 14 318
General medical conditions 25,473 5,578 1,549 1,562 5,504 1,531 445 2,447 44,091
Total 40,337 10,033 3,315 2,162 13,878 3,930 543 17,662 91,861
Includes ambulance services, outpatient medications, oral agents, insulin, and supplies.
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someone with diabetes.
Dividing health care expenditures by
the size of the population with and with-
out diabetes creates estimates of per cap-
ita expenditures (Table 10). On average,
people with diabetes incurred approxi-
mately $13,243 in health care expendi-
tures in 2002 across the health care
components included in this study. Peo-
ple without diabetes incurred approxi-
mately $2,560 in expenditures, for a ratio
of 5 to 1. This comparison is slightly
higher than ratios estimated by ADA (2)
and Rubin et al. (27), who found a four-
fold difference in average annual health
care expenditures for people with diabe-
tes compared with others. However, this
ratio somewhat overstates the impact of
diabetes on per capita costs because the
demographic composition of the popula-
tion with diabetes differs substantially
fromthedemographiccompositionofthe
population without diabetes. The popu-
lation with diabetes tends to be older, on
average, than the population without di-
abetes.
We derived an age-adjusted annual
per capita expenditure of $5,642 to con-
trol for differences in demographic char-
acteristics of the population with diabetes
compared with the nondiabetic popula-
tion, yielding a ratio of 2.4-to-1 for
health care expenditures among people
with and without diabetes. This ratio pre-
vails, roughly, across cost components,
ranging from a high of 2.7 to 1 for home
health services to a low of 2 to 1 for emer-
gency services.
Indirect costs attributable to
diabetes
At an annual cost of $7.5 billion, more
than 176,000 cases of permanent disabil-
ity in 2002 are attributable to diabetes




without diabetes U.S. total
Attributable to diabetes














Nursing home 13,878 15 25,860 28 67,915 93,775
Physician’so f ﬁce 10,033 7 18,433 13 118,484 136,917
Hospital outpatient 3,315 7 5,911 12 42,330 48,240
Emergency 2,162 4 4,424 9 44,952 49,375
Outpatient medication 5,516 9 9,636 15 55,074 64,710
Home health 3,930 18 6,230 28 15,873 22,103
Hospice care 543 14 1,020 26 2,960 3,981
Ambulance services 146 5 281 10 2,433 2,714
Insulin and delivery supplies 6,991 100 6,991 100 NA 6,991
Oral agents 5,009 100 5,009 100 NA 5,009
Total health care costs 91,861 11 160,041 19 704,991 865,032













Hospital inpatient $ 6,309 $1,289 4.9 $2,971 2.1
Nursing home 2,140 247 8.7 991 2.2
Physician’so f ﬁce 1,525 430 3.5 695 2.2
Hospital outpatient 489 154 3.2 215 2.3
Emergency 366 163 2.2 187 2.0
Home health 516 58 8.9 190 2.7
Hospice 84 11 7.9 39 2.1
Ambulance services 23 9 2.6 11 2.1
Outpatient medication 797 202 3.9 341 2.3
Insulin & delivery supplies 579 NA NA NA NA
Oral agents 414 NA NA NA NA
Total health care costs $13,243 $2,560 5.2 $5,642 2.4
*Adjusted to reﬂect demographic composition of the population with diabetes.
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sizeable decrease from the cost of disabil-
ity in the 1998 report (2), which used the
present value of lost lifetime earnings to
estimate the cost of disability. We use av-
erage annual lost earnings, estimated at
$42,462 per case, to represent the pro-
ductivity loss associated with the disabil-
ity. Disability cases where diabetes is
listed as the primary cause accounts for
more than two-thirds of total cases attrib-
uted to diabetes. Cases where cardiovas-
culardiseaseislistedastheprimarycause
of disability accounts for 7% of all cases
attributed to diabetes.
The estimated number of deaths at-
tributable to diabetes is derived from in-
stances where the primary cause of death
is diabetes, renal disease, cerebrovascular
disease, or cardiovascular disease. The
etiological fractions used to estimate
healthcareuseattributabletodiabetesare
applied to the estimates of the number of
deaths—by age, sex, race/ethnicity, and
primary cause of death—to estimate
deaths attributable to diabetes. Estimated
lost years of life are based on comparing
timing of premature death to life expect-
ancy (28).
In2002,anestimated186,000deaths
were attributable to diabetes (Table 12).
An estimated 19% of all deaths for which
cardiovascular disease is listed as the pri-
mary cause of death are attributed to dia-
betes, and this accounts for 108,000 (58%)
of all deaths attributable to diabetes.
This ﬁnding is consistent with the
major ﬁndings of a study by DeStefano
and Newman (29), which ﬁnds that cor-
onary heart disease is the leading cause of
mortality among people with diabetes.
DeStefano and Newman ﬁnd that for
younger people (i.e., men under age 45
years and women under age 55 years),
peoplewithdiabeteshada13-foldgreater
risk of coronary heat disease mortality
than people without diabetes when con-
trolling for other coronary heart disease
risk factors. The Centers for Disease Con-
trol and Prevention reports that adults
with diabetes have heart death rates that
are two to four times higher than those of
adults without diabetes (30). An esti-
mated 2,000 deaths with renal disease as
the primary cause are attributed to diabe-
tes. Geiss et al. (31) found that age-
adjusted renal mortality rates for people
with diabetes are more than 2.5 times the
rates for people without diabetes.
National cost of diabetes
Combining estimates of health care ex-
penditures and productivity losses attrib-
utabletodiabetesyieldsanestimateofthe
national cost of diabetes (Table 13). In
2002, the estimated cost of diabetes was
approximately $132 billion, of which ap-
proximately $92 billion (70%) was addi-
tional health care expenditures and $40
billion(30%)waslostproductivitydueto
disability and early mortality. Institu-
tional care (i.e., hospital inpatient care
and nursing home care) was the largest
component of health care costs and com-
prised 41% of the national cost of diabe-
tes. Outpatient care, at $20 billion in
2002,comprised15%ofthenationalcost
of diabetes. At $17.5 billion, the cost of
outpatient medication and supplies com-
prised 13% of the national cost of diabe-
tes.
As the U.S. population grows in size,
ages, and becomes more racially and eth-
nically diverse, the size of the population
diagnosedwithdiabeteswillgrow,evenif
current patterns in diabetes prevalence
remain unchanged. Using current diabe-
tesprevalenceratesappliedtoCensusBu-
reau population projections, the national
cost of diabetes could grow to $156 bil-
lion by 2010 (in 2002 dollars) and to
$192billionby2020(Fig.4).Directmed-
ical costs could increase from $92 billion
in 2002 to $138 billion in 2020, whereas
indirectcostsfromlostproductivitycould
increase from $40 billion in 2002 to $54
billion in 2020. The actual future cost of
diabetesislikelytobesubstantiallyhigher
than these projected amounts if the prev-
alence of diabetes continues to grow—
especially for type 2 diabetes, which is
correlated with the growing problem of
obesity in the U.S.—even after control-




is more than double what spending
would be without diabetes. This costs the
U.S. economy an estimated $92 billion in
higherhealthcareexpenditures.Lostpro-
ductivity attributed to diabetes resulting
from lost workdays, lost home services,
permanent disability, and premature
mortality is estimated at $40 billion.
Compared to people without diabetes,
people with diabetes and their families
bear a disproportionate share of health
care expenditures.











Diabetes 121,893 69 5.2
Cardiovascular disease 12,110 7 0.5
Renal disease 3,887 2 0.2
Other diagnoses 38,584 22 1.6
Total 176,475 100 7.5
Table 12—Mortality costs attributable to diabetes, 2002














Diabetes 72 100 1,080 10,622
Renal disease 2 6 31 273
Cerebrovascular disease 4 12 54 305
Cardiovascular disease 108 19 1,357 10,358
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likely understates the true burden of dia-
betes for the following reasons:
● This estimate omits the cost of intangi-
bles such as pain and suffering, the cost
ofcareprovidedbyinformalcaregivers,
and administrative costs of insurers.
● The cost components included in this
analysis account for only 58% of the
estimated $1.5 trillion in U.S. health
care expenditures in 2002. For exam-
ple, over-the-counter medications and
sundries, which Martin et al. (26) esti-
mate at $122 billion in 1998, are omit-
tedfromthecostestimate.Whereasthe
areas of health care expenditures ana-
lyzed are those where health care use
patterns have been shown to differ by
diabetes status, there are several areas
omittedfromtheanalysiswherepeople
with diabetes probably use services at
higherratesthanpeoplewithoutdiabe-
tes, e.g., dental care, optometry care,
and the use of licensed dietitians.
● The average price per health service
used could differ by diabetes status. If
health care conditions classiﬁed as
“general medical conditions” (e.g.,
pneumonia) are more severe for people
with diabetes than without diabetes,
then the cost estimate would be too
low. The study controls for differences
in health care use attributable to diabe-
tes, e.g., the number of hospital inpa-
tient days, but does not control for
differencesinmixofhealthcareprofes-
sionals seen (e.g., if people with diabe-
tes are more likely to see a specialist
instead of a primary care physician).
● In this study, people with undiagnosed
diabetes are categorized with the non-
diabetic population. If per capita use of
healthcareservicesisgreaterforpeople
with undiagnosed diabetes than for
people without diabetes, the health
care costs attributable to diabetes will
be underestimated.
Future research might investigate the
cost of diabetes in these areas omitted
from the present analysis.
The estimated national cost of diabe-
teswascalculatedusingprevalence-based
cost-of-illness methods with data from
1998 through 2002. For some compo-
nents of the cost estimate (e.g., the cost of
supplies), multiple data sources were an-
alyzed and the results were compared to
ensure robust results. One change from
the approach used in ADA’s 1998 study
was to combine multiple years of national
health use databases to increase sample
size and allow for ﬁner disaggregation of
the U.S. population—both of which
would improve the accuracy of the ﬁnd-
ings, because the prevalence of diabetes
and the use of health care services varies
substantially by age-group, sex, and race/
ethnicity. Greater disaggregation also al-
lows for more accurate projections of the
national cost of diabetes in future years as
the U.S. population grows, ages, and be-
comes more racially and ethnically di-
verse. However, if lifestyle trends in the
U.S.(suchasthegrowingproblemofobe-
sity) increase diabetes prevalence rates,
future costs could grow in excess of those
extrapolated based on current prevalence
rates.
Although this study includes the
same cost components of ADA’s 1998
Figure 4—Projected impact of changing demographic characteristics on the national cost of
diabetes: 2002–2020 (in 2002 billions of dollars).
Table 13—Total cost of diabetes, 2002
Cost component






Health care expenditures 91,861 70
Institutional care 54,215 41
Hospital inpatient care 40,337 31
Nursing home care 13,878 11
Outpatient care 20,130 15
Physician ofﬁce-based care 10,033 8
Emergency care 2,162 2
Ambulance services 146 0
Hospital outpatient care 3,315 3
Home healthcare 3,930 3
Hospice care 543 0
Outpatient medication and supplies 17,516 13
Outpatient medication 5,516 4
Insulin and delivery supplies 6,991 5
Oral agents 5,009 4
Indirect costs due to lost productivity 39,810 30
Lost work days 4,503 3
Restricted activity days 6,256 5
Mortality 21,558 16
Permanent disability 7,494 6
Total cost 131,672 100
*Cost component percentages do not necessarily sum to category totals because of rounding.
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tes-attributed costs between 1997 and
2002 for some cost components reﬂects a
reﬁnement in the cost estimates as op-
posedtoanactualchangeintruecosts.As
discussed previously, the 1998 study es-
timated disability-related costs at $32.5
billion in 1997, compared with the cur-
rent study, which estimates disability-
related costs at $7.5 billion. Much of the
decrease in attributed costs is the result of
using foregone expected annual expendi-
turesinsteadofforegoneexpectedlifetime
earnings to estimate the pecuniary cost of
lost productivity, which may have been
an inadvertent overstatement in the
previous report. This large decrease in at-
tributed costs is offset by substantially
higher cost estimates for certain health
care components such as nursing home
care,homehealthcare,andphysicianofﬁce-
based care.
One factor contributing to the large
increase in attributed cost for nursing
homecareisthehigherestimatedcostper
day in nursing homes ($169 per day used
in this study vs. $79 per day [$97 per day
in 2002 dollars] used in the 1998 study).
This study estimates a much higher cost
of home health care services, with an es-
timated 18% of total U.S. home health
care services costs attributed to diabetes
compared with an estimated 0.2% of the
total U.S. cost of home health care ser-
vices attributed to diabetes in the 1998
study. Martin et al. (26) estimated na-
tional expenditures of approximately $30
billion for home health care in 1997,
comparedwiththeestimateof$19billion
in the 1998 report (2).
Eliminating or reducing the health
problemscausedbydiabetesthroughfac-
tors such as better access to preventive
care, more widespread diagnosis, more
intensive disease management, and the
adventofnewmedicaltechnologiescould
signiﬁcantlyimprovethequalityoflifefor
people with diabetes and their families,
while at the same time potentially reduc-
ing national expenditures for health care
services and increasing productivity in
the U.S. economy.
In conclusion, the cost of diabetes,
both direct medical expenditures and the
costs of foregone productivity, is esti-
mated to have been $132 billion in 2002.
This represents a substantial cost burden
to society and, in particular, to those in-
APPENDIX
Chronic complications of diabetes ICD-9 MEPS codes
Neurological symptoms
Myasthetic syndromes in diseases classiﬁed
elsewhere (amyotrophy)
358.1
Other speciﬁed idiopathic peripheral neuropathy 356.8
Mononeuritis of upper and lower limbs 354, 355
Arthropathy associated w/neurological disorders
(Charcot’s arthropathy)
713.5
Peripheral autonomic neuropathy 337.1
Polyneuropathy in diabetes 357.2
Neuralgia, neuritis, and radiculitis, unspeciﬁed 729.2
Diabetes with neurological complications 250.6
Occlusion of cerebral arteries 434
Hemorrhagic stroke 430–432
Late effects of cerebrovascular disease 438
Occlusion of stenosis of pre-cerebral arteries 433
Other and ill-deﬁned cerebrovascular disease 437
Acute, but ill-deﬁned, cerebrovascular disease 436
Transient ischemic attack 435
Peripheral vascular disease
Atherosclerosis 440
Embolism and thrombosis, structure of artery 444, 447.1
Other peripheral vascular disease 443
Other disorders of circulatory system 459
Phlebitis and thrombophlebitis, portal vein
thrombosis, and thrombolism and venous
thrombolism
451, 452
Other venous embolism and thrombolism 453
Varicose veins of lower extremities 454
Gangrene and amputations 785.4, 885–887, 895–897
Chronic ulcer of skin 707
Cardiovascular disease
Aortic and other aneurysms 441, 442
Hypotension 458
Angina 413
Conduction disorders and cardiac dysrhythmias 426–427
Atherosclerotic cardiovascular disease 429.2
Cardiomegaly 429.3
Cardiomyopathy 425




Diabetes w/peripheral circulatory disorders 250.7
Myocardial degeneration 429.1
Myocardial infarction 410, 412
Other chronic ischemic heart disease 414
Hypertension 401–405
Renal Complications
Infections of kidney 590
Other disorders of bladder 596
Cystitis 595





Continued on following page
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Nevertheless,thisestimateisconservative
and probably underestimates the true
cost of the disease.
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Appendix continued
Chronic complications of diabetes ICD-9 MEPS codes
Renal failure and its sequelae 584, 586, 588
Other disorders of kidney and ureter 593
Urinary tract infection 599.0
Diabetes and renal complications 250.4
Chronic renal failure (end-stage renal disease) 585
Endocrine/metabolic complications
Dwarﬁsm-obesity syndrome 259.4
Glycogenosis and galactosemia 271.0, 271.1








Other speciﬁed endocrine disorders 259.8




Other retinal disorders 362
Vascular disorders of the iris and ciliary body 364.0, 364.4
Disorders of the optic nerve and visual pathways 377
Diabetes with ophthalmic complications 250.5
Cataract 366
Glaucoma 365
Visual disturbance, low vision, blindness 368–369
Other complications
Bacteremia, bacterial infection, Coxsackie virus 079.2, 790.7
Candidiasis of skin and nails 112.3
Chronic osteomyelitis of the foot 730.17
Other and unspeciﬁed noninfectious
gastroenteritis and colitis
558.9
Impotence of organic origin 607.84
Infective otitis externa 380.1
Degenerative skin disorders 709.3
Candidiasis of vulva and vagina 112.1
Cellulitis 681, 682
Diabetes with other speciﬁed manifestations 250.8
Diabetes with unspeciﬁed complication 250.9
Other bone involvement in disease classiﬁed
elsewhere
731.8
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